Under the terms of the agreement, PolyMedics Innovations will serve as the Company’s exclusive distributor of RECELL® in
PolyMedics Innovations, a privately-owned company specializing in the commercialization of innovative biomaterials and systems for the treatment of wounds, operates a robust distribution network of over 40 global markets.
“Our partnership with PolyMedics Innovations represents the first step of our strategic global expansion,” said
About
In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in
To learn more, visit www.avitamedical.com.
About
PolyMedics Innovations (PMI) is a R&D-driven specialist in innovative biomaterials for the effective treatment of wounds. PMI is an owner-managed
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational, and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
Authorized for release by the Chief Financial Officer of
Investor & Media Contact:Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.com
Source:
2023 GlobeNewswire, Inc., source